YMAB Rasio rega marang prakiraan pendapatan Y-mAbs Therapeutics
The reliability of pediatric drug delivery via strict temperature control ensures the stability of Y-mAbs Therapeutics (YMAB) supply chains. The company's forward P/S serves as an indicator of investor confidence, where 4.60 indicates the current level of the metric. The business adheres to bioethics in testing and eco-friendly waste disposal, while regular sales of approved drugs support the cash flow for new research.
Rincian analitis perusahaan Y-mAbs Therapeutics
- rega saham lan target rega konsensus:
- data kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Y-mAbs Therapeutics|YMAB - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Y-mAbs Therapeutics|YMAB - Kewajiban utang agregat|Utang marang nilai buku Y-mAbs Corp|YMAB - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Y-mAbs Therapeutics|Rasio cepet ymabs.com
- rincian asil keuangan lan kelipatan valuasi:
YMAB - Penghasilan resik perusahaan|Bathi sing dikarepake Y-mAbs Therapeutics|YMAB - Nilai perusahaan marang bathi resik|Pangali Forward P/E YmAbs|YMAB - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Y-mAbs Corp|YMAB - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Y-mAbs Therapeutics|YMAB - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan ymabs.com|YMAB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Y-mAbs Therapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analisis perusahaan:Y-mAbs Therapeutics, Inc. (YMAB)
Institutional capital assesses the attractiveness of Y-mAbs Therapeutics (YMAB) through the lens of expected cash flows from the commercialization of orphan drugs and the development of its oncology pipeline. By analyzing the forward P/S trend, which compares the current market value of the business to projected revenue, investors determine the degree of asset overvaluation and the reliability of its fundamental value relative to the risks of new therapy approvals.
Perusahaan pesaing
BeiGene - Multiplikator forward rega marang pendapatan|Prakiraan rega marang pendapatan Halozyme Therapeutics, Inc.|RVMD - Rasio rega marang prakiraan pendapatan|Ascentage Pharma Corp (AAPG) - Multiplikator forward rega marang pendapatan|CGON: Multiplikator Forward P/S|urogen.com (URGN) - Multiplikator Forward P/S|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Rasio kapitalisasi marang dodolan sing dikarepake Delcath Corp|Aura Biosciences, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CADL|ARAY: Multiplikator forward rega marang pendapatan|SELLAS Life Sciences - Rasio rega marang pendapatan sing dikarepake|ACTU: Multiplikator Forward P/S|Citius Oncology Inc - Rega forward marang dodolan|HURA (TuHURA Biosciences Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep protaratx.com TARA|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|WHWK (aadibio.com) - Rega forward marang dodolan|Multiplikator Forward P/S TCRX (TScan Therapeutics, Inc.)|Multiplikator Forward P/S Champions Oncology Inc CSBR|XBIT - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan CVM|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep radiopharmtheranostics.com (RADX)|Multiplikator forward rega marang pendapatan ARTV|Multiplikator Forward P/S Adlai Nortye Limited|Multiplikator forward rega marang pendapatan VERU (Veru Inc.)|Rasio rega marang pendapatan sing dikarepake TPST|Multiplikator Forward P/S XLO (Xilio Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake Renovaro Biosciences (RENB)|Mural Bio - Multiplikator Forward P/S|Kairos Pharma Ltd (KAPA) - Multiplikator forward rega marang pendapatan|onkuretherapeutics.com (OKUR) - Rasio rega marang prakiraan pendapatan|GDTC - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CRIS|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Apollomics Corp APLM|Rasio rega marang prakiraan pendapatan Tharimmune Corp (THAR)|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Multiplikator Forward P/S GNPX (Genprex, Inc.)|Multiplikator Forward P/S Calidi Biotherapeutics Inc. CLDI|Sunshine Biopharma, Inc. - Multiplikator Forward P/S|XBIO: Rasio rega marang prakiraan pendapatan|SLRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Kitov Pharma|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S beigene.com|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|elevationoncology.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ICAD (iCAD)|IKNA - Multiplikator forward rega marang pendapatan|Notable Labs, Ltd. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viracta Therapeutics|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Inc - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan AAPGV
